Knowthestock.com
CNAT - Conatus Pharmaceuticals, Inc.

Sell

Weak GrowthEarnings/Profit is Negative

18%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -86.97%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -931.51%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 4.37
Debt Ratio is 0.53
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.03
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Conatus Pharmaceuticals, Inc. (CNAT) - http://www.conatuspharma.com
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.
Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Steven J. Mento
Employees - 6
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.